Duodenal alpha‐Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease
Background The role of the gut‐brain axis has been recently highlighted as a major contributor to Parkinson's disease (PD) physiopathology, with numerous studies investigating bidirectional transmission of pathological protein aggregates, such as α‐synuclein (αSyn). However, the extent and the...
Saved in:
Published in | Movement disorders Vol. 38; no. 5; pp. 885 - 894 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.05.2023
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
The role of the gut‐brain axis has been recently highlighted as a major contributor to Parkinson's disease (PD) physiopathology, with numerous studies investigating bidirectional transmission of pathological protein aggregates, such as α‐synuclein (αSyn). However, the extent and the characteristics of pathology in the enteric nervous system have not been fully investigated.
Objective
We characterized αSyn alterations and glial responses in duodenum biopsies of patients with PD by employing topography‐specific sampling and conformation‐specific αSyn antibodies.
Methods
We examined 18 patients with advanced PD who underwent Duodopa percutaneous endoscopic gastrostomy and jejunal tube procedure, 4 untreated patients with early PD (disease duration <5 years), and 18 age‐ and ‐sex‐matched healthy control subjects undergoing routine diagnostic endoscopy. A mean of four duodenal wall biopsies were sampled from each patient. Immunohistochemistry was performed for anti‐aggregated αSyn (5G4) and glial fibrillary acidic protein antibodies. Morphometrical semiquantitative analysis was performed to characterize αSyn‐5G4+ and glial fibrillary acidic protein–positive density and size.
Results
Immunoreactivity for aggregated α‐Syn was identified in all patients with PD (early and advanced) compared with controls. αSyn‐5G4+ colocalized with neuronal marker β‐III‐tubulin. Evaluation of enteric glial cells demonstrated an increased size and density when compared with controls, suggesting reactive gliosis.
Conclusions
We found evidence of synuclein pathology and gliosis in the duodenum of patients with PD, including early de novo cases. Future studies are required to evaluate how early in the disease process duodenal pathology occurs and its possible contribution to levodopa effect in chronic patients. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
---|---|
Bibliography: | Full financial disclosures and author roles may be found in the online version of this article. A.A. has received compensation for consultancy and speaker‐related activities from UCB, Boehringer Ingelheim, Ever Pharma, General Electric, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Theravance Biopharma, Jazz Pharmaceuticals, Roche, and Medscape; has received research support from Bial, Lundbeck, Roche, Angelini Pharmaceuticals, Horizon 2020 Grants 825785 and 101016902, Ministry of Education University and Research Grant ARS01_01081, Cariparo Foundation, and Movement Disorders Society for NMS Scale validation; and has served as consultant for Boehringer–Ingelheim for legal cases on pathological gambling. G.G.K. has served as an advisor for Biogen; has received royalty for 5G4 synuclein antibody and publishing royalties from Wiley, Cambridge University Press, and Elsevier; has received grants from Edmond J. Safra Philanthropic Foundation, Rossy Family Foundation, The Michael J. Fox Foundation, Parkinson Canada, and Canada Foundation for Innovation. All other authors declare no conflict of interest. Aron Emmi and Michele Sandre contributed equally to this work. Relevant conflicts of interest/financial disclosures ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0885-3185 1531-8257 1531-8257 |
DOI: | 10.1002/mds.29358 |